Literature DB >> 28406063

Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.

Antoine M Klauser1, Oliver T Wiebenga2, Anand Jc Eijlers3, Menno M Schoonheim3, Bernard Mj Uitdehaag4, Frederik Barkhof5, Petra Jw Pouwels6, Jeroen Jg Geurts3.   

Abstract

BACKGROUND: Multiple sclerosis is characterized by white matter lesions, which are visualized with conventional T2-weighted magnetic resonance imaging (MRI). Little is known about local metabolic processes preceding the appearance and during the pathological development of new lesions.
OBJECTIVE: To identify metabolite changes preceding white matter (WM) lesions and pathological severity of lesions over time.
METHODS: A total of 59 relapsing-remitting multiple sclerosis (MS) patients were scanned four times, with 6-month intervals. Imaging included short-TE magnetic resonance spectroscopic imaging (MRSI) and diffusion tensor imaging (DTI).
RESULTS: A total of 16 new lesions appeared within the MRSI slab in 12 patients. Glutamate increased (+1.0 mM (+19%), p = 0.039) 12 and 6 months before new lesions appeared. In these areas, the increase in creatine and choline 6 months before until lesion appearance was negatively correlated with radial diffusivity (ρ = -0.73, p = 0.002 and ρ = -0.72, p = 0.002). Increase in creatine also correlated with the increase of axial diffusivity in the same period (ρ = -0.53, p = 0.034). When splitting the lesions into "mild" and "severe" based on radial diffusivity, only mild lesions showed an increase in creatine and choline during lesion formation ( p = 0.039 and p = 0.008, respectively).
CONCLUSION: Increased glutamate heralded the appearance of new T2-visible WM lesions. In pathologically "mild" lesions, an increase in creatine and choline was found during lesion formation.

Entities:  

Keywords:  DTI; MRI; MRS; MRSI; Multiple sclerosis; metabolite

Mesh:

Substances:

Year:  2017        PMID: 28406063     DOI: 10.1177/1352458517702534

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions?

Authors:  Eva Heckova; Bernhard Strasser; Gilbert J Hangel; Michal Považan; Assunta Dal-Bianco; Paulus S Rommer; Petr Bednarik; Stephan Gruber; Fritz Leutmezer; Hans Lassmann; Siegfried Trattnig; Wolfgang Bogner
Journal:  Invest Radiol       Date:  2019-04       Impact factor: 6.016

2.  Reduction of AMPA receptor activity on mature oligodendrocytes attenuates loss of myelinated axons in autoimmune neuroinflammation.

Authors:  Kirsten S Evonuk; Ryan E Doyle; Carson E Moseley; Ian M Thornell; Keith Adler; Amanda M Bingaman; Mark O Bevensee; Casey T Weaver; Booki Min; Tara M DeSilva
Journal:  Sci Adv       Date:  2020-01-08       Impact factor: 14.136

Review 3.  The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.

Authors:  Ido Ben-Shalom; Arnon Karni; Hadar Kolb
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 4.  Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

Authors:  Emily Kamma; Wendy Lasisi; Cole Libner; Huah Shin Ng; Jason R Plemel
Journal:  J Neuroinflammation       Date:  2022-02-10       Impact factor: 8.322

Review 5.  Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.

Authors:  Martin Zirngibl; Peggy Assinck; Anastasia Sizov; Andrew V Caprariello; Jason R Plemel
Journal:  Mol Neurodegener       Date:  2022-05-07       Impact factor: 18.879

6.  Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.

Authors:  Kirsty E Waddington; Artemis Papadaki; Leda Coelewij; Marsilio Adriani; Petra Nytrova; Eva Kubala Havrdova; Anna Fogdell-Hahn; Rachel Farrell; Pierre Dönnes; Inés Pineda-Torra; Elizabeth C Jury
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.